The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Istituto Ortopedico Rizzoli1,000 enrolled

Overview

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Sarcoma, Ewing

Interventions

patientsOTHER

Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis; * Patients with age ≥ 2 years; * Minimum follow-up duration of 2 years; * Medical records, complete blood work and instrumental examinations; Regular follow-up. Exclusion Criteria: * Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.

Locations (1)

Istituto Ortopedico Rizzoli

Bologna, Italy

Outcomes

Primary Outcomes

5-year survival

Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental laboratory, clinical and instrumental factors

Time frame: at baseline (Day0)

Secondary Outcomes

Rate of local recurrence

Evaluation of the rate of local recurrence and distant metastasis in relation to prognostic factors histological, laboratory, clinical and instrumental factors;

Time frame: at baseline (Day0)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.